Loading patent…
OwnerPeter Zipfel, Christina Skerka +1inventors
InventorsPeter Zipfel, Christina Skerka, Reinhard Wallich
Estimating the term…
The present invention relates to the identification of novel regulators of the innate immune system, in particular the complement system. More particularly, the present invention relates to specific C5 convertase inhibitors. These novel inhibitors are particularly useful for treating inflammatory diseases involving the complement system. In a first aspect, the present invention focuses on the use of CFHR proteins and functional fragments or functional derivatives thereof for preventing inflammatory reactions. In a further aspect, the present invention focuses on the use of said CFHR proteins for inactivating complement activation during transplantation and dialysis and for coating devices which come into contact with blood or body fluids, in particular implants. The invention furthermore provides a pharmaceutical composition comprising functional CFHR protein in combination with functional factor H. In a further aspect, the present invention focuses on providing monoclonal antibodies which specifically detect CFHR proteins, and on the use thereof in methods of determining CFHR in body fluids. These methods are particularly suitable for diagnosing inflammatory diseases.
Use of a CFHR molecule, in particular a CFHR protein, or a functional fragment or functional derivative thereof, the latter inhibiting the enzyme C5 convertase, for the treatment or prophylaxis of autoimmune diseases and inflammatory reactions.
Use of a CFHR protein or of a functional derivative or of a functional fragment thereof for inactivating the complement activation, in particular during transplantation or dialysis.
Use of a CFHR protein or of a functional fragment or of a functional derivative thereof for coating implants and surfaces which may come into contact with body fluids.
Coating for devices coming into contact with body fluids, in particular plasma or blood, characterized in that the surface of said coating comprises CFHR protein, a functional fragment or functional derivative thereof.
Device coming into contact with body fluids and in particular blood, more specifically implantable device, characterized in that CFHR protein, a functional derivative or functional fragment thereof has been applied to the surface.
Pharmaceutical composition comprising functional CFHR protein in combination with functional factor H and optionally with further pharmaceutically acceptable diluents, carriers and excipients.
Monoclonal antibody which specifically detects a CFHR protein immunohistologically and immunobiochemically and which can specifically bind to human CFHR, more specifically CFHR1 protein, wherein said monoclonal antibody has the same properties as the monoclonal antibody of the JHD-7.10.1 hybridoma cell line, deposited in accordance with the Budapest Treaty with the DSMZ, Brunswick, Germany, DSM ACC 2978.
Method according to claim 20 for diagnosing hemolytic uremic syndrome, further comprising the step of determining autoantibodies in a body fluid of the individual.
Dependencies are inferred from the claim text.